Recent Updates
Recently added Catalysts

quadrivalent influenza split vaccine

Phase 1

Influenza | Monoclonal antibody | Infectious Disease |Co-Diagnostics, Inc.|Last Updated: Oct 28, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment120
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05212623A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 MonthsPHASE1 COMPLETED 120Oct 26, 2021Jun 16, 2022Oct 28, 20221 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Incidence of adverse events within 7 days after each vaccination in the participants aged 6-35 months. (Including abnormal laboratory test indicators and clinical significance)
On day 7 after each dose
Secondary Endpoints
Incidence of adverse events from the first dose to 30 days after the second dose in the participants aged 6-35 months.
Time Frame: within 30 days after the second dose
Incidence of serious adverse events (SAE) till the 6 months after the second dose in the participants aged 6-35 months.
within 6 months after the second dose
HI antibody-positive conversion rate in each group 30 days after the second vaccination in the participants aged 6-35 months.
on day 30 after the second vaccination
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Group AEXPERIMENTALSubjects received 2 doses of 0.25 mL of quadrivalent influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (Four types of virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata).
Group BEXPERIMENTALSubjects received 2 doses of 0.5 mL of quadrivalent influenza vaccine, 4 weeks apart. Each 0.5-ml dose contained 15 μg of hemagglutinin per strain.(Four types of virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata).
Group CACTIVE_COMPARATORSubjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 type of virus strains, including BY).
Group DACTIVE_COMPARATORSubjects received 2 doses of 0.25 mL of influenza vaccine, 4 weeks apart. Each 0.25-ml dose contained 7.5 μg of hemagglutinin per strain (3 types of virus strains, including BV).
Interventions
NameTypeDescription
quadrivalent influenza split vaccineBIOLOGICALThis vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
Influenza virus split vaccineBIOLOGICALThis vaccine is produced by Changchun Sponsor Institute of Biological Products Co., Ltd. Subjects will receive two doses of quadrivalent influenza vaccine administered 4 weeks apart by intramuscular injection
Unlock Study Design Details
Eligibility Criteria
Age Range6 Months — 35 Months
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy infants and young children aged 6-35 months, provide vaccination certificate and birth medical certificate. * The subject or legal guardian can provide with informed consent and sign the informed consent form. * The subjects or legal guardians are able to and willing t...

Countries:China
Unlock Eligibility Criteria